Pitch Book for Medical Devices(English)

Summary of Pakistan Medical Device Industry Investment Pitchbook (July 2026) This pitchbook is tailored for Chinese investors for the Pakistan-China B2B Investment Conference in Karachi, focusing on massive medical device import substitution opportunities in Pakistan, covering macro market data, local industrial foundation, five investment entry models, priority product lines, government regulatory reforms, preferential policies, a disposable syringe financial case, risk analysis and official supporting institutions. ## 1. Pakistan Macro & Medical Device Market Overview 1. Basic national fundamentals Pakistan has a population of over 240 million (5th globally), a workforce of around 79 million with a median age of roughly 20. Its GDP stands at about USD 410 billion; economic growth rebounds above 3% annually, while inflation has dropped sharply from 24% to single digits under IMF-backed reforms. 2. Huge import-dependent medical device market The total domestic end-market size reaches approximately USD 700 million with an annual growth rate of 8–15%. Over 90% of medical devices rely on imports; recorded sea-port CIF imports alone exceeded USD 328 million in FY 2024–25. A total of 1,451 importers from 68 countries operate in the market. 3. China’s dominant supply position China ranks the largest supplier, accounting for 40.7% of Pakistan’s medical device imports, followed by Japan (16.1%), Malaysia (7.7%), Germany (5.9%) and the US (4.5%). The top five source countries occupy 75% of total import volume. 4. Major import product breakdown - Surgical & general disposables: 41.1% (syringes, IV sets, surgical gloves, sutures, dressings, etc.) - Imaging & monitoring equipment: 25.1% (CT, MRI, X-ray, ultrasound, anaesthesia devices) - IVD lab consumables & test kits: 16.8% - Hospital furniture & orthopaedic devices: 6.5% - Cardiology intervention products: 5.8% - Dialysis equipment & disposables: 4.7% 5. Core demand drivers Expanding public & private tertiary hospitals, surging chronic disease prevalence (diabetes, cardiovascular, renal illnesses), large-scale government institutional tenders, plus export potential to the Middle East, Central Asia and Africa. ## 2. Local Manufacturing & Raw Material Base 1. Existing domestic capacity There are 94 registered local manufacturers producing around 33 types of medical devices, mainly mature low-end products: wound dressings, syringes, PPE, rapid diagnostic kits, dialysis concentrates. High-end equipment, stents and ventilators remain untapped greenfield markets. Most local factories adopt full self-operation, leaving assembly, OEM and joint venture cooperation space wide open. 2. Abundant local raw material advantages - Textile & non-woven materials (4th largest cotton producer) for gauze, masks, surgical gowns; - Sialkot stainless steel industrial cluster for surgical instruments; - Local pharmaceutical chemicals for disinfectants, dialysis solutions; - Rich salt and gypsum reserves for saline and orthopaedic plaster. - Only medical-grade PP/PVC resin relies on imports, creating another upstream investment opportunity under the national petrochemical plan. ## 3. Five Investment Entry Paths for Chinese Partners 1. Trade & distribution: Cooperate with local distributors to import high-end imaging, lab analysers; low capital threshold. 2. SKD/CKD assembly: Assemble imported parts for syringes, infusion sets, rapid test kits; moderate investment. 3. OEM/Toll production: Utilise existing local factories to produce dressings, gloves and Class A non-sterile consumables. 4. Equity joint venture: Build dedicated production lines for syringes, IV cannulas, dialysis supplies; access institutional bulk orders. 5. Full greenfield integrated plant: Realise full upstream & downstream production including local resin manufacturing, covering sterile and non-sterile products. ### Priority investment product tiers - Tier 1 (highest import volume): IV sets, disposable syringes, general surgical disposables; - Tier 2: Rapid IVD test kits, PPE, dialysis consumables; - Tier 3: Imaging & patient monitoring equipment (adopt progressive localised assembly). ### Low-cost Class A beachhead products Non-sterile Class A items (gloves, adhesive tapes, gauze, disinfectants) require minimal investment, simple licensing procedures and rely on domestic textile raw materials, ideal for early market entry. ## 4. Groundbreaking Regulatory & Government Support Policies 1. Dramatically simplified registration DRAP launched a fully digital online licensing system in July 2025, cutting registration time from 18–24 months to only 20 working days with electronic certificates and paperless single-window customs clearance. The first national Medical Device Policy is under formulation with industrial stakeholders participating in drafting. 2. Multi-authority one-stop services - DRAP: Device registration & supervision; - SIFC (Prime Minister’s office): Top-tier single-window investment coordination; - BOI: Foreign investment approval acceleration; - Ministry of Health: National localisation procurement policies. 3. Special Economic Zone incentives 100% foreign ownership permitted, full profit & capital repatriation rights; tax holidays until 2035; zero customs duties on production machinery and raw materials; fully serviced industrial land near ports in Karachi and Bin Qasim. CPEC logistics provides stable cross-border supply chains between China and Pakistan. ## 5. Typical Financial Case: 3ml + 5ml Auto-Disable Syringe Production Line - Total CAPEX: USD 2.7 million, consisting of equipment, factory building and working capital; - Financing structure: 70% bank debt / 30% equity, 14% annual interest, 5-year loan term; - Annual output: 120 million syringes under two-shift operation; - Stable annual revenue: USD 3.35 million; EBITDA margin 33–43%; - Payback period: Around 3 years (shortens to 2.2 years if needles and resin are localised); annual joint venture return approx 22%. Cost structure: Raw materials account for 52% of revenue, labour only 9% due to high automation. Localising resin and needles lifts gross margins by about 7 percentage points. ## 6. Key Investment Risks & Official Mitigation Solutions | Risk Category | Risk Level | Investor Measures | Government Support | |---------------|------------|-------------------|--------------------| | Profit & capital repatriation | High | Prioritize export revenue for USD income; apply SIFC approval for remittance | SIFC single-window fast-track for central bank clearance | | PKR currency depreciation | High | Sign USD-index sales contracts, take local currency loans | Local currency financing channels | | Potential rollback of tax incentives | Medium-High | Sign legal grandfather clauses valid until 2035 | SIFC legal protection for SEZ policy commitments | | High domestic GST | Medium-High | Locate factories inside EPZs/SEZs for duty exemptions | Industry advocacy by HDAP for tax equalisation | | Fluctuating public tender demand | Medium | Sign long-term supply contracts with private hospitals & NGOs | Government procurement preference for local-made devices | | Reliance on imported medical resin | Medium | Build safety stock, jointly develop local resin plants | Tariff relief for imported polymer raw materials | | Evolving device registration rules | Medium | Hire local authorised regulatory representatives | Fully digital 20-day fast review channel | ## 7. Core Investment Conclusion Pakistan boasts a massive, fast-growing medical device market with over 90% import reliance, complete textile, metal and chemical raw material supply chains, and revolutionary streamlined 20-day digital DRAP registration. Supported by SEZ tax holidays, CPEC logistics and institutional bulk procurement guarantees, Chinese investors have five flexible entry models ranging from trading to full integrated manufacturing. Disposable consumable projects such as auto-disable syringes deliver stable 33%+ gross margins and a 3-year payback cycle, representing low-risk, high-return import substitution opportunities covering domestic demand and export markets across South Asia, the Middle East and Africa. Official contact channels of DRAP, SIFC, BOI and the local medical device association are provided for follow-up cooperation.